P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB

Mazyar Shadman, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Jeff Sharman, Syed F. Zafar, Kunthel By, Aileen Cohen, Rocco Crescenzo, Adam Idoine, Ian W. Flinn

Open source

DOI
10.1097/01.hs9.0000969436.70152.b3
Published
2023-08
Container
HemaSphere
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000969436.70152.b3,
  title = {P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB},
  author = {Mazyar Shadman and Moshe Y. Levy and Ryan Porter and John M. Burke and Jennifer L. Cultrera and Jamal Misleh and Jeff Sharman and Syed F. Zafar and Kunthel By and Aileen Cohen and Rocco Crescenzo and Adam Idoine and Ian W. Flinn},
  year = {2023},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000969436.70152.b3},
  url = {https://doi.org/10.1097/01.hs9.0000969436.70152.b3}
}

RIS

TY  - JOUR
TI  - P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB
AU  - Mazyar Shadman
AU  - Moshe Y. Levy
AU  - Ryan Porter
AU  - John M. Burke
AU  - Jennifer L. Cultrera
AU  - Jamal Misleh
AU  - Jeff Sharman
AU  - Syed F. Zafar
AU  - Kunthel By
AU  - Aileen Cohen
AU  - Rocco Crescenzo
AU  - Adam Idoine
AU  - Ian W. Flinn
PY  - 2023
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000969436.70152.b3
UR  - https://doi.org/10.1097/01.hs9.0000969436.70152.b3
ER  - 

APA

Shadman, M., Levy, M. Y., Porter, R., Burke, J. M., Cultrera, J. L., Misleh, J., Sharman, J., Zafar, S. F., By, K., Cohen, A., Crescenzo, R., Idoine, A., & Flinn, I. W. (2023). P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB. HemaSphere. https://doi.org/10.1097/01.hs9.0000969436.70152.b3

Source records